IL-25 and IL-4 signaling in the setting of infection or allergic responses can drive Type 2 inflammation. IL-25 requires the IL-17 receptor B (IL-17Rb) to mediate signaling through nuclear factor k B (NF-kB) transcriptional activation. Despite the known coexistence of these two cytokines in the Type 2 inflammatory environment, collaborative signaling between the IL-4 and IL-25 axes is poorly explored. Here we demonstrate IL-4 induction of both IL-25 and IL-17Rb protein in human lung tissue culture, primary alveolar macrophages, and the THP-1 monocytic cell line. IL-4 treatment triggers gene transcription for both IL-25 and IL-17Rb but does not alter the receptor mRNA stability. Genetic antagonism of the IL-4 second messenger, signal transducer and activator of transcription 6 (STAT6), with small interfering RNA (siRNA) blunts IL-17Rb mRNA induction by IL-4. IL-25 induces signaling through the canonical NF-kB pathway, and STAT6 or NF-kB signaling inhibitors prevent IL-17Rb expression. Blockade of IL-25 with monoclonal antibody suppresses NF-kB activation after IL-4 treatment, and IL-4-mediated induction of IL-17Rb is suppressed by IL-25 siRNA.
IL-25 and IL-17Rb promoter regions harbor putative NF-kB and STAT6 consensus sites, and chromatin immunoprecipitation identified these transcription factors in complex with the IL-17Rb 59 untranslated region. In bronchoalveolar lavage RNA preparations, IL-25 and IL-17Rb mRNA transcripts are increased in asthmatics compared with healthy control subjects, and IL-25 transcript abundance correlates strongly with IL-4 mRNA levels. Thus, these results indicate that IL-4 signaling up-regulates the IL-25 axis in human monocytic cells, and that IL-25 may provide autocrine signals in monocytes and macrophages to sustain IL-17Rb expression and predispose to alternative activation.
Clinical Relevance
This work provides new mechanistic insight into a relatively unexplored receptor (IL-17Rb) and its molecular regulation in innate immune responses.
In T-helper type 2 (Th2)-associated disease states such as allergic asthma, IL-4 signaling plays a key role in the immune response by inducing eosinophilia, airway hyperresponsiveness, mucin expression, and granulocyte activation, thereby serving as a target for biologic therapeutics (1) . IL-4 activation of IL-4R and Janus kinase 3 (JAK3) leads to phosphorylation and dimerization of signal transducer and activator of transcription 6 (STAT6). Phosphorylated Stat6 (p-Stat6) migrates to the nucleus to bind IL-4-responsive gene promoters and drive the Th2 inflammatory cascade (2) . The IL-25 cytokine (also known as IL-17E) is also implicated in eliciting a Th2-mediated immune response via activation of NF-kB through tumor necrosis factor receptor associated factor 6 (TRAF-6) activation (3, 4) . IL-25 and IL-17Rb signaling has been described in epithelial cells (5) and T cells. Allergen challenge promotes expression of IL-25 and IL-17Rb in serum and whole lungs, and IL-17Rb is detected within a myeloid cell population (6) . The importance of IL-25 signaling is underscored by the fact that animals deficient in IL-17Rb fail to mount a robust Type 2 or Th2 cytokine response (6) . T cells are known to up-regulate IL-17Rb in response to IL-25, suggesting a feed-forward cellular response that can drive Th2 differentiation (7) . Although monocytic cells and tissue macrophages are known to be IL-4 sensitive, their expression of IL-25 and IL-17Rb is not well characterized. We hypothesized that IL-4 is important for molecular regulation of the IL-25 and IL-17Rb signaling axis in monocytic cells, and that the mechanistic cross talk between these factors may be important for monocytic cell differentiation in Type 2 inflammation signaling.
In human studies, patients with asthma have been shown to display higher levels of IL-25 than normal, and allergen exposure was shown to increase IL-17Rb 1 cells (8, 9) . Furthermore, allergen exposure was found to induce IL-17Rb on dendritic cells (DCs) (I) THP1 cells were treated with actinomycin D (Actino) at the indicated concentrations for 30 min before IL-4 (50 ng/ml) and IL-17Rb mRNA was assayed using quantitative PCR. Data are representative of at least three experiments performed on different days. *P , 0.05 and **P , 0.01 by two-sided t test (G and I) or ANOVA (F and H). veh, vehicle.
in asthmatics, but not nondiseased subjects (10 
Materials and Methods

Cell Cultures and Reagents
Immortalized human bronchial epithelial Beas-2B cells and THP1 monocytic cells were purchased from the ATCC (Bethesda, MD). BEAS-2B cells were maintained in HITES medium supplemented with 10% FBS. THP1 cells were grown in RPMI medium with 10% FBS. All cells were kept in a 37 8 C incubator with 5% CO 2 as described previously (13) . Alveolar macrophage primary cells were obtained by bronchoscopy of human donor lungs (see below) using an Ambu bronchoscope and sterile PBS. Bronchoalveolar lavage (BAL) samples were strained through a 100 mg filter before centrifugation at 1,000 rpm for 15 
Human Tissues
Donor human lungs not accepted for transplant were obtained through the University of Pittsburgh Committee for Oversight of Research and Clinical Training Involving Decedents. Donor medical records were deidentified and IRB approval was not required to access these tissues. Organs were considered appropriate for study if there was no evidence of parenchymal lung disease, gas exchange was within normal limits before harvest, and organs could be processed with , 6 h cold ischemic time. Bronchoscopy was performed as described above for alveolar macrophages. For tissue slices, localized lesions (e.g., solitary nodules) were avoided, and single lung segments were dissected and warmed in a 37 8 C water bath for 30 min. Low-melting-point agarose (2%) in PBS (Invitrogen Ultrapure) was maintained at 37 8 C. The lung segments were filled with agarose by instillation into airways via syringe with an 18-gauge cannula and inspected for appropriate expansion, followed by airway clamping and packing in ice for 30 min or until the agarose had set. Tissue was cut to block size (2 cm 3 1 cm 3 1 cm) and sliced in ice-cold saline with a vibratome (Leica VT 1200) at a slice thickness of 300 mm. Uniform slices were sectioned into 1 cm 3 1 cm sections and cultured in RPMI containing penicillinstreptomycin and amphotericin B without serum in 12-well dishes at 37 8 C in a tissue incubator with 5% CO 2 . The medium was changed after 2 h and experiments were performed in 1 ml of medium after overnight incubation. Slices were treated with 50 ng/ml of IL-4 for 4 h and then homogenized for immunoblotting and mRNA analysis. To evaluate induction of the IL-25 axis in lung tissue by IL-4, we treated human lung slices in an organ culture system with 50 ng/ml recombinant IL-4 for 4 h and observed robust IL-17Rb induction as an z56 kD protein ( Figure 1A ). To determine whether this tissue IL-4 response was cell-type specific, we evaluated cellular responses from a human airway epithelial cell line BEAS-2B and alveolar macrophages. Although the BEAS-2B epithelial cells responded to IL-4 with appropriate phosphorylation of the z110 kD STAT6 (p-Stats6) second messenger, very little baseline or induced expression of IL-17Rb or IL-25 was seen after 4 h of IL-4 treatment ( Figure 1B ). Human alveolar macrophages from BAL, however, showed increased expression of both IL-25 cytokine (z18 kD) levels and IL-17Rb ( Figure 1C ). Likewise, monocytic (THP1) cells displayed time-dependent IL17Rb induction after IL-4 stimulation ( Figure 1D ). IL-25 was also induced in a concentration-wise fashion after IL-4 treatment in these myeloid-like cells ( Figure 1E ). Quantitative PCR showed significant increases in expression of IL-25 and IL-17Rb mRNA after IL-4 exposure in both THP1 cells (Figures 1F and 1H ) and IL-17Rb in alveolar macrophages ( Figure 1G ). These effects of Il-4 were not seen in Beas-2B cells (data not shown). To assess the underlying mechanisms, cells were treated with actinomycin D to inhibit mRNA synthesis and exposed to IL-4. In these studies, the IL-4-stimulated induction of IL-17Rb mRNA was abolished, suggesting that new IL-17Rb transcripts resulted from increased gene transcription rather from an extended half-life of abundant mRNAs ( Figure 1H ).
IL-4 Induction of IL-17Rb Requires STAT6 Activation
We next evaluated the necessity of STAT6 signaling for the induction of IL-17Rb in THP1 cells. With IL-4 treatment, there was rapid activation of STAT6 with phosphorylation of tyrosine 461 (Figure 2A) , which preceded the appearance of IL-17Rb. In a subpopulation of cells, a fraction of STAT6 was trafficked to the nucleus within 30 min ( Figures 2B and 2C, arrows) , and we observed by immunoblotting (Figure 2A ) and fluorescence microscopy ( Figure 2C ) that IL17Rb protein was highly expressed in THP1 cells 3 h after IL-4 treatment. IL-17Rb staining was not exclusive to the membrane during this induction, presumably because it was being translated and trafficked at these time points. Cellular depletion of STAT6 using two separate siRNA constructs effectively blocked IL-4-driven induction of IL-17Rb by IL-4 ( Figure 2D ) by reducing the cellular mass of total and phosphorylated STAT6 ( Figure 2E ).
NF-kB Activation Potentiates IL-17Rb Expression
Because IL-4 stimulation induced both IL-25 and its cognate receptor in THP cells, we next tested whether the NF-kB signal response was elicited by IL-25 and after IL-4 treatment. IKK phosphorylates IkB to liberate the p65 subunit of NF-kB for nuclear translocation and signaling. IL-25 was sufficient to induce activation of IKK in THP1 cells, and we observed that IKK was rapidly phosphorylated after IL-25 exposure ( Figure 3A) . We also observed that IkB, the negative regulator of NF-kB, was Figure 3B, upper blot) . This phosphorylation of IkB led to its degradation ( Figure 3B, middle panel) . To determine whether this activation of NF-kB impacted transcription of IL-17Rb, we used small-molecule antagonists for either STAT6 (AS1517499) (14) or NF-kB (BAY11-7082) (15) and evaluated the cellular response to IL-4 treatment. Both inhibitors significantly suppressed induction of IL-17Rb mRNA ( Figure 3C ) and protein ( Figure 3D ).
IL-25 Signaling Is Required to Sustain IL-17Rb Expression
Because IL-4 induces IL-25 expression and NF-kB signaling is required for sustained IL-17Rb expression, we evaluated whether IL-25 itself might generate this second signal needed to reinforce its receptor abundance. When THP1 cells or macrophages were pretreated with monoclonal antibody (mAb) to IL-25 for 1 h before IL-4 treatment, we observed a distinct reduction in both IL-17Rb protein induction ( Figure 4A ) and mRNA ( Figure 4B ). We next evaluated cells for nuclear translocation of the NF-kB subunit p65 (also known as RELA) with IL-4 treatment and observed that p65 nuclear abundance was increased after IL-4 treatment, an effect that was blocked by the IL-25 antibody ( Figure 4C ). Accordingly, IL-25 blockade caused a decrease in IKK phosphorylation 30 min and 4 h after IL-4 treatment ( Figure 4D ). Although IL-17Rb levels were similarly induced after 30 min of IL-4, the abundance of IL-17Rb elicited at the 4 h time point was significantly reduced when the IL-25 blocking antibody was present ( Figure 4D ). To corroborate the effects observed with the IL-25 antibody, we used two separate constructs of siRNA targeting IL-25, and again observed that IL-4 failed to induce robust IL-17Rb expression at 4 h when the cells were treated with siRNA, despite intact STAT6 phosphorylation responses ( Figure 4E ). These siRNA constructs likewise suppressed IL-4 induction of both IL-25 ( Figure 4F ) and IL-17Rb ( Figure 4G To evaluate the specific association of transcription factors STAT6 and NF-kB RELA protein with the 59 untranslated region of the IL-17Rb open reading frame gene, we evaluated the primary sequence of the promoter to identify putative binding sites for NF-kB (16) and STAT6 (17) . We identified one consensus match for STAT6 binding and two putative NF-kB binding domains ( Figure 5A ). The IL-25 promoter also possesses consensus sequences for these transcription factors ( Figure E2 ). We performed ChIP with antibodies to NF-kB or STAT6 after a 4-h treatment with IL-4, followed by PCR amplification of a small (225 bp) amplicon from the IL-17Rb promoter that contains the consensus STAT6 site and is within 700 bp of both of the * * NF-kB sites identified. Figure 5B shows an amplification of this 300 bp fragment from PCR reactions with whole nuclear genomic DNA (Input, which is diluted 1:10) or DNA preparations after ChIP for NF-kB and STAT6 without and with IL-4 treatment for 4 h.
IL-25 and IL-17Rb Transcripts Are Increased in Asthmatic Airway Specimens
To evaluate whether the link among Type 2 inflammation, IL-4, and the IL-25 signal axis is intact in human subjects with asthma, we analyzed RNA preparations from BAL samples from healthy control subjects or patients with a clinical diagnosis of asthma (clinical data for these subjects are presented in Table E1 ). The mean transcript levels for IL-25, IL-17Rb, IL-4, and IL-4Ra1 were increased in the asthmatics compared with healthy controls (Figures 6A-6D ). When we evaluated gene associations for each of the transcripts tested, we found a strong correlation between the levels of IL-25 and IL-4 mRNA ( Figure 6E ). We observed no significant association between other genes (data not shown), and stratification of the asthmatics into mild/moderate and severe phenotypes did not provide sufficient statistical power to resolve differences between any of the measured transcripts. When we evaluated the abundance of cytokine transcripts for an IL-4 and IL-25 correlation with the oral corticosteroid dose among the five subjects taking oral corticosteroids, we found a trend toward an inverse correlation that was not significant (data not shown). These data suggest that within airways, the IL-25 signaling axis is up-regulated in a subset of asthmatics compared with healthy controls, and that IL-4 and IL-25 induction may be linked.
Discussion
In this study, we observed in alveolar macrophages and monocytes that IL-4 signaling induced coordinate expression of the cytokine IL-25 and its IL-17Rb receptor. The data suggest that in a feed-forward signaling loop, IL-25 strengthens the IL-4 signal to sustain IL-17Rb expression in these cells, maintaining signaling capacity for the Type 2 cytokine IL-25. The best characterization to date of IL-17Rb expression on myeloid cells in airways was achieved by Petersen and colleagues in granulocytic cells, which the authors termed type 2 myeloid (T2M) cells (6) . These T2M cells (which are CD11b 1 and Gr1 mid, with a subset being IL-17Rb 1 ) were instrumental in the cockroach allergen response in a 2-wk airway hypersensitivity model. Genetic deletion of IL-17Rb significantly lessened allergen sensitivity in these mice, and the phenotype was reconstituted with airway adoptive transfer of wild-type T2M cells. These IL-17Rb
1 T2M cells responded robustly to IL-25, with subsequent activation of the IL-4 promoter. However, the authors did not investigate the mechanistic basis for the induction of IL-17Rb in the T2M cell population.
Our study shows a converse but consistent biological relationship between these two cytokines, where IL-4 (18) . In this study, we found a positive association between IL-25 and IL-4 transcript abundances from unprovoked BAL samples from several asthmatics, whereas BAL isolated from other asthmatics and healthy controls had nearly undetectable levels of transcripts for either cytokine. Our observations are consistent with other human studies highlighting the importance of IL-25 signaling, with reports of increased serum IL-25 and expression of IL-17Rb on cells from patients with asthma. In a recent clinical study, IL-17Rb expression was evaluated on DCs isolated from blood and sputum samples several days after subjects were challenged with inhaled allergen (10) . Both myeloid and plasmacytoid DCs showed IL-17Rb expression 24 h after allergen exposure, and the myeloid DCs showed a strong correlation between IL-17Rb and other markers of Th2 and asthma phenotypes (16) . It is worth remarking that in our study we detected these Type 2 cytokine transcripts in some patients with severe asthma, whereas other patients had no detectable amount of mRNA for these factors, pointing to the broad diversity of asthma endotypes within the spectrum of inflammatory obstructive lung disease (19) .
Precisely how the cells mentioned in the above studies initiate and sustain the expression of IL-17Rb is not fully understood; however, the current study fills in some gaps in our understanding of the relevant pathways. It is conceivable that antigen receptors (either IgE or receptors on Th2 cells) react to allergen exposure by releasing cytokines (e.g., IL-4, IL-13, and IL-25) with transcriptional activation of the IL-17Rb gene through the coordinated activities of Stat6 and NF-kB factors (as shown here) to induce a stable population of IL-17Rb 1 myeloid cells. These cells could then propagate Type 2 immune pathology, as previously reported in animal studies and humans with Type 2-driven illness. Interestingly, our results demonstrate that IL-4 robustly up-regulates IL-17Rb mRNA, exceeding the induction by IL-4 at steadystate protein levels. This observation suggests a more complex, distinct mode of IL-4 regulation at both the IL-17Rb transcript and protein levels. Possible explanations for these effects include a discordance in transcript versus protein stability in the cell, more inefficient protein translation compared with rates of mRNA synthesis, and altered protein degradation before membrane trafficking. In addition, protein detection is critically dependent on antibody affinity with exposure of epitopes that may be masked depending on post-translational modifications and subcellular location of individual substrates.
Signal amplification is a common theme in immunobiology as systems of cells and cytokines organize themselves into a coordinated response, and autocrine macrophage stimulation seems to play a role in these systems (20) . In a previous study, the IL-17A signaling axis was shown to display a similar interplay with the IL-6 signaling axis in an autoimmune arthritis model, such that both cytokines were required for a full phenotype and robust expression of the downstream genes KC and macrophage inflammatory protein (21) . That study similarly invoked a dual-transcription factor model, with STAT3 and NF-kB synergistically participating in the transcriptomic inflammatory response, analogous to the observations we made in the current study with STAT6 and NF-kB. Coordinated gene expression in response to pathogen and tissue signals is a driver of cell polarization and identity, and dissection of the interplay of cellular responses to multiple inputs remains an interesting area of ongoing study. n Author disclosures are available with the text of this article at www.atsjournals.org.
